Che K, Lin K, Li S. Comments on "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial". J Gastroenterol Hepatol 2026 Jul 7. doi: 10.1111/jgh.70558.
PMID: 42413998